Rafael Zubiran
Overview
Explore the profile of Rafael Zubiran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wolska A, Sampson M, Zubiran R, Meeusen J, Donato L, Jaffe A, et al.
Front Cardiovasc Med
. 2024 Nov;
11:1452869.
PMID: 39526185
Background: The triglyceride (TG) content of low-density lipoprotein (LDL-TG) has been shown to be more predictive of atherosclerotic cardiovascular disease (ASCVD) events than the cholesterol content of LDL (LDL-C). The...
2.
Zubiran R, Cruz-Bautista I, Aguilar-Salinas C
Diabetes Ther
. 2024 Jul;
15(9):1979-2000.
PMID: 39080218
There is a gap of knowledge about the clinical and pathophysiological implications resulting from the interaction between primary hyperlipidemias and type 2 diabetes (T2D). Most of the existing evidence comes...
3.
Zubiran R, Neufeld E, Dasseux A, Remaley A, Sorokin A
Cardiol Ther
. 2024 Jul;
13(3):465-491.
PMID: 39031302
Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality despite effective low-density lipoprotein cholesterol-targeted therapies. This review explores the crucial role of inflammation in the residual risk...
4.
Adams-Huet B, Zubiran R, Remaley A, Jialal I
J Clin Lipidol
. 2024 Jun;
18(4):e518-e524.
PMID: 38834412
Background: Metabolic syndrome (MetS) is a cluster of cardio-metabolic features portending an increased risk for both type 2 diabetes mellitus (T2DM) and premature atherosclerotic cardiovascular disease (ASCVD). Homeostasis model assessment...
5.
Garcia E, Shalaurova I, Matyus S, Freeman L, Neufeld E, Sampson M, et al.
Molecules
. 2024 Feb;
29(3).
PMID: 38338310
Lipoprotein X (LP-X) is an abnormal cholesterol-rich lipoprotein particle that accumulates in patients with cholestatic liver disease and familial lecithin-cholesterol acyltransferase deficiency (FLD). Because there are no high-throughput diagnostic tests...
6.
Coverdell T, Sampson M, Zubiran R, Wolska A, Donato L, Meeusen J, et al.
Lipids Health Dis
. 2024 Feb;
23(1):43.
PMID: 38331834
Background: The accurate measurement of Low-density lipoprotein cholesterol (LDL-C) is critical in the decision to utilize the new lipid-lowering therapies like PCSK9-inhibitors (PCSK9i) for high-risk cardiovascular disease patients that do...
7.
Sampson M, Wolska A, Zubiran R, Cole J, Amar M, Remaley A
Expert Rev Mol Diagn
. 2024 Jan;
24(1-2):123-133.
PMID: 38252511
Background: Lipid testing for atherosclerotic cardiovascular disease (ASCVD) risk is often performed every 4-6 years, but we hypothesized that the optimum time interval may vary depending on baseline risk. Research...
8.
Zubiran R, Vargas-Vazquez A, Olvera F, Cruz-Bautista I, Martagon-Rosado A, Sampson M, et al.
Atherosclerosis
. 2023 Nov;
386:117364.
PMID: 37984194
Introduction: Low-density cholesterol (LDL-C) has long been estimated by the Friedewald formula (F-LDL-C); however, this method underestimates LDL-C in patients with hypertriglyceridemia (HTG) or low LDL-C levels. The Martin (M-LDL-C)...
9.
Cole J, Zubiran R, Wolska A, Jialal I, Remaley A
J Clin Med
. 2023 Sep;
12(17).
PMID: 37685804
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death worldwide and the risk of a major cardiovascular event is highest among those with established disease. Ongoing management of these...
10.
Martagon A, Zubiran R, Gonzalez-Arellanes R, Praget-Bracamontes S, Rivera-Alcantara J, Aguilar-Salinas C
Atherosclerosis
. 2023 Aug;
394:117213.
PMID: 37580206
Atherosclerotic cardiovascular disease (ASCVD) represents the primary cause of mortality among patients with Type 2 Diabetes Mellitus (T2DM). In this population, High-Density Lipoprotein (HDL) particles exhibit abnormalities in number, composition,...